Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer

Cancer

Volumn 116, Issue 13, 2010, Pages 3224-3232

  Klarenbach, Scott ^a   Manns, Braden ^b   Reiman, Tony ^c   Reaume, Martin Neil ^d   Lee, Helen ^b   Lloyd, Anita ^a   Wiebe, Natasha ^a   Hemmelgarn, Brenda ^b   Tonelli, Marcello ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Anemia; Cancer; Cost effectiveness; Erythropoietin analogs

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION TREE; HEALTH CARE COST; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; THROMBOEMBOLISM;

ANEMIA; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HEMATINICS; HUMANS; MIDDLE AGED; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE;

EID: 77954284610     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25052     Document Type: Article

References (47)

1. Wilson J, Yao GL, Raftery J, et al. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess. 2007;11:1-202, iii-iv.
2. Ossa DF, Briggs A, McIntosh E, Cowell W, Littlewood T, Sculpher M. Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods. Pharmacoeconomics. 2007;25: 223-237.
3. Ortega A, Dranitsaris G, Puodziunas AL. What are cancer patients willing to pay for prophylactic epoetin alfa? A costbenefit analysis. Cancer. 1998;83:2588-2596. (Pubitemid 29019581)
4. Tonelli M, Hemmelgarn B, Reiman T, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ. 2009;180:E62-E71.
5. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009;373:1532-1542.
6. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299: 914-924.
7. Sheffield R, Sullivan SD, Saltiel E, Nishimura L. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother. 1997;31:15-22. (Pubitemid 27030059)
8. Fagnoni P, Limat S, Chaigneau L, et al. Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer. Support Care Cancer. 2006;14:1030-1037. (Pubitemid 44451308)
9. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008;26:132-149.
10. Guidelines for the economic evaluation of health technologies. 3rd ed. Ottawa, Canada: Canadian Agency for Drugs and Technology in Health. 2006.
11. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003;6:9-17. (Pubitemid 36228345)
12. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol. 2005;23:2606-2617.
13. Kettelhack C, Hones C, Messinger D, Schlag PM. Randomized multicentre trial of the influence of recombinant human erythropoietin on intraoperative and postoperative transfusion need in anaemic patients undergoing right hemicolectomy for carcinoma. Br J Surg. 1998;85:63-67. (Pubitemid 28034114)
14. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B; Epoetin Alfa Study G. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865-2874.
15. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002;94:1211-1220.
16. Smith RE, Jr, Aapro MS, Ludwig H, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008;26:1040-1050.
17. Gordon D, Nichols G, Ben-Jacob A, Tomita D, Lillie T, Miller C. Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study. Oncologist. 2008;13:715-724. (Pubitemid 351904916)
18. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer. 1993;29A(suppl 2):S2-S8.
19. Kosmadakis N, Messaris E, Maris A, et al. Perioperative erythropoietin administration in patients with gastrointestinal tract cancer: prospective randomized double-blind study. Ann Surg. 2003;237:417-421. (Pubitemid 38176458)
20. Chang J, Couture F, Young S, McWatters KL, Lau CY. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol. 2005;23:2597-2605. (Pubitemid 46179448)
21. Savonije JH, van Groeningen CJ, van Bochove A, et al. Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial. Eur J Cancer. 2005;41:1560-1569.
22. Wright JR, Ung YC, Julian JA, et al. Randomized, doubleblind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007;25:1027-1032.
23. Aapro M, Leonard RC, Barnadas A, et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol. 2008;26:592-598.
24. Thomas G, Ali S, Hoebers FJ, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol. 2008;108:317-325.
25. Overgaard J, Hoff C, Sand Hansen H, et al. Randomized study of the importance on novel erythropoiesis stimulating protein (Aransep) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) - the Danish Head and Neck Cancer Group DAHANCA 10 rand [abstract]. Eur J Cancer. 2007;5S:7.
26. Results from a phase 3, randomized, double-blind, placebo-controlled study of darbepoetin alfa in subjects with previously untreated extensive-stage small-cell lung cancer (SCLC) treated with platinum plus etoposide chemotherapy. Study: 20010145. Thousand Oaks, CA: Amgen. 2007.
27. O'Shaughnessy JA, Vukelja SJ, Holmes FA, et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer. 2005;5:439-446.
28. Boogaerts M, Coiffier B, Kainz C; Epoetin beta QOL Working Group. Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer. 2003;88:988-995.
29. Strauss HG, Haensgen G, Dunst J, et al. Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer. Int J Gynecol Cancer. 2008;18:515-524. (Pubitemid 351668300)
30. ten Bokkel Huinink WW, de Swart CA, van Toorn DW, et al. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol. 1998;15:174-182.
31. Charu V, Belani CP, Gill AN, et al. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial. Oncologist. 2007;12:727-737. (Pubitemid 47036207)
32. MacDougall DA, Feliu AL, Boccuzzi SJ, Lin J. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm. 2006;63(20 suppl 6):S5-S15.
33. Cremieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB. Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia. Pharmacoeconomics. 1999;16(5 pt 1):459-472.
34. Barosi G, Marchetti M, Liberato NL. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy- induced anaemia. Br J Cancer. 1998;78:781-787. (Pubitemid 28418314)
35. Transfusion Transmitted Injuries Section: About Risks of Blood Transfusion. Public Health Agency of Canada. Available at: http://www.ab. bluecross.ca/hcai-iamss/tti-it/riskseng. php. Accessed March 2009.
36. Kleinman S, Chan P, Robillard P. Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev. 2003;17:120-162. (Pubitemid 36539254)
37. Amin M, Fergusson D, Wilson K, et al. The societal unit cost of allogenic red blood cells and red blood cell transfusion in Canada. Transfusion. 2004;44:1479-1486. (Pubitemid 39318984)
38. Alberta Blue Cross. Alberta Health and Wellness Drug Benefit List Criteria for Special Authorization of Select Drug Products. 2008. Edmonton, Canada: Alberta Health and Wellness. Available at: http://www.ab.bluecross.ca/ dbl/pdfs/ahwdbl-sec3.pdf. Accessed March 2009.
39. Statistics Canada. Consumer Price Index for Canada [health care (not seasonally adjusted) 1972-1996]. 1997; Cat no 62-553. Ottawa, Canada: Statistics Canada.
40. Tonelli M, Hemmelgarn B, Reiman T, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ. 2009;180:E62-71.
41. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146:473-481.
42. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ. 2004;329:224-227. (Pubitemid 39013284)
43. Patrick DL, Gagnon DD, Zagari MJ, Mathijs R, Sweetenham J. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer. 2003;39:335-345.
44. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage. 2002;24:547-561. (Pubitemid 36120443)
45. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics. 1999;15:141-155. (Pubitemid 29093257)
46. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095-1108. (Pubitemid 127453463)
47. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int. 1996;50:235-242. (Pubitemid 26323718)